Oral squamous cell carcinoma (OSCC) is the most common head and neck cancer, annually accounting for more than 250 000 new cases worldwide ([@bib20]). Despite advances in diagnostic, surgical and chemoradiation techniques, only 50% of OSCC patients survive beyond 5 years ([@bib8]); in fact, survival rates in OSCC have remained unchanged for the last five decades. A better understanding of the underlying biological mechanisms, and their impact on OSCC prognosis, could provide more effective treatments and improve survival rates.

Hypoxia is rare in normal oral epithelial tissue ([@bib9]) but is common within the tumour microenvironment. Hypoxic tumours are associated with tumour invasiveness, metastasis and an overall poor prognosis ([@bib19]; [@bib43]; [@bib41]). The effectiveness of traditional chemotherapy and radiotherapy is dependent on inducing apoptosis in tumour cells; however, hypoxia selects for tumour cells with reduced sensitivity to apoptotic stimuli by suppressing pro-apoptotic BAK/BAX signalling ([@bib13]; [@bib32]). Hypoxic sensitisers and hypoxia-specific toxins offer significant potential for improving treatment efficacy in OSCC. However, identifying hypoxic tumours in the clinical setting is presently a barrier to the effective application of hypoxia-targeting/sensitising therapeutics ([@bib43]).

Several methods have been used to identify hypoxic tumours; however, there is currently no single gold-standard technique. Direct measurement by oxygen electrode is sensitive but must reconcile substantial intra-tumoural heterogeneity and anatomic restrictions for access. Exogenous markers such as bioreductive drugs (e.g., pimonidazole) are convenient to administer, and easily imaged, but the extent of hypoxia required for activation may not necessarily reflect clinically relevant tumour hypoxia and may be subject to incomplete distribution due to ineffective perfusion of some tumour areas ([@bib43]). Immunohistochemistry (IHC)-based detection of tumour hypoxia by staining for endogenous markers of hypoxia (EMH) is both cost effective and clinically feasible, but there is a lack of agreement as to which EMH most reliably indicate an adverse tumour phenotype and poor prognosis ([@bib37]). Expression of the EMH carbonic anhydrase IX (CAIX) has been shown to be consistently associated with prognosis across several cancer sites, including head and neck squamous cell carcinoma (HNSCC; [@bib17]; [@bib24]; [@bib4], [@bib5]; [@bib30]). However, many studies have reported discrepancies between CAIX expression and other measures of tissue hypoxia, such as pO~2~ ([@bib24]), or bioreductive drug markers, such as pimonidazole ([@bib22]; [@bib29]; [@bib43]). This discordant distribution is likely due to differences in the threshold of activation for bioreductive drugs (exogenous) *vs* endogenous markers, the half-life of other hypoxic indicators (e.g., HIF1*α*), fluctuating concentration of oxygen within tumour tissues ([@bib36]) and oxygen-independent regulation of CAIX expression. We propose that the prognostic value of CAIX will be improved by considering additional factors that influence CAIX expression.

Carbonic anhydrase IX expression is regulated by the transcription factor HIF1*α* ([@bib38]). HIF1*α* stability and activity are principally regulated by the pO~2~ levels within cells; however, increased HIF1*α* stability and transcriptional activity can also be achieved under normoxic/mildly hypoxic conditions by signalling through proliferation-inducing pathways, such as phosphatidylinositol 3-kinase, nuclear factor kappa B, AKT and Her2 ([@bib27]; [@bib15]; [@bib23]; [@bib34]; [@bib1]; [@bib24]). Highly hypoxic tumour cells are characterised by poor proliferation ([@bib40]; [@bib21]; [@bib43]); therefore, cells exhibiting both proliferation and EMH expression could represent cells exposed to additional proliferative stimuli or alternative regulation of EHM and not necessarily diminished oxygen availability. Mildly and moderately hypoxic tumours may remain proliferative ([@bib16]) and express high levels of CAIX because of the presence of aberrant cellular signalling pathways that impact HIF1*α* stability and activity ([@bib33]; [@bib24]). This suggests that the measurement of EMH within the tumour may not accurately reflect the level of tumour hypoxia.

We recently reported that CAIX expression in the tumour stroma (sCAIX) is a stronger predictor of HNSCC patient survival than CAIX expression in the tumour ([@bib4], [@bib5]). This may reflect the relatively normal nature of stromal cells compared with tumour cells, in which genomic instability leads to deregulation of hypoxic signalling ([@bib18]; [@bib44]). However, the presence of proliferative tumour cells surrounding the stroma might be a consequence of growth factor and cytokine signalling in the tumour microenvironment. These same factors can induce pO~2~-independent stabilisation of HIF1*α* ([@bib24]) and upregulate CAIX expression in the stroma. We hypothesised that proliferation-associated sCAIX expression attenuates the association between sCAIX expression and survival outcomes in OSCC. In the present study, we account for proliferation-associated, hypoxia-independent CAIX expression by incorporating Ki67 status to stratify patients with high sCAIX expression. The biological relevance of our prognostic signature is supported by its association with reduced BAX expression ([@bib13]; [@bib32]). This approach identifies patients with the least favourable prognosis who would potentially benefit most from the inclusion of additional therapies to their current treatment regimens.

Materials and methods
=====================

Patient cohort
--------------

Institutional ethics approval was obtained from the Conjoint Health Research Ethics Board at the University of Calgary, in accordance with the Tri-Council Policy Statement on Research with Human Subjects. The retrospective study cohort has been previously described ([@bib3]) and included 102 treatment-naive, surgically resected patients with OSCC diagnosed between 1998 and 2005 at the Foothills Medical Centre, Calgary, Alberta, Canada. All patients were treated by two head and neck surgeons (JCD and Dr. T Wayne Matthews). Although these patients comprise a subset of oral cancer patients diagnosed during this period, there were no significant differences in clinical and demographic characteristics between these patients and our population-based prospective clinical cohort diagnosed between 2009 and 2012, indicating that these patients are representative of the disease burden in Alberta, Canada (data not shown). Post-operative radiotherapy was included based on the presence of metastatic lymph nodes, extra-capsular spread (ECS) or positive surgical margins. A clinical outcome database and associated tissue microarray (TMA) series were constructed as described previously ([@bib3]). Treatment-naive, formalin-fixed, paraffin-embedded (FFPE) tumour samples were available for 87 of the 102 patients. Tissue cores suitable for the evaluation of CAIX and Ki67 were available for 60 of these 87 patients. Triplicate cores from pathologically confirmed tumour-bearing regions of each FFPE tumour block were included for each patient to account for intra-tumour heterogeneity ([@bib7]). Five samples of normal oral cavity squamous epithelium, separate from the tumour-containing regions of archived FFPE tissue blocks, were also included in the TMAs as reference samples to establish biomarker levels in normal tissue ([@bib3]).

Quantitative fluorescence IHC
-----------------------------

We used fluorescence IHC and the HistoRx AQUA platform ([@bib6]) to quantify the expression of CAIX, Ki67 and BAX in each TMA core. The details of the staining conditions for CAIX and vimentin ([@bib5]), Ki67 ([@bib25]) and BAX ([@bib3]) have been previously described. Briefly, TMA slides were stained using a 1 : 500 dilution of anti-vimentin (280618, rat mAb, R&D Systems, Burlington, ON, Canada) and a 1 : 1000 dilution of anti-CAIX (ab15086, rabbit pAb, Abcam, Cambridge, UK). For Ki67, a 1:5000 dilution of anti-Ki67 (MIB1, mouse mAb, Dako, Burlington, ON, Canada) was used and for Bax, a 1:5000 dilution of anti-Bax (E63, rabbit mAb, Epitomics, Burlingame, CA, USA) was used. The respective secondary antibodies, rat HRP (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and mouse or rabbit Envision+ (Dako) were used along with the sequential application of the fluorophores tyramide-Cy3, for detection of vimentin and Ki67 or tyramide-Cy5, for the detection of CAIX and Bax (Perkin--Elmer, Waltham; MA, USA). A 1 : 100 dilution of a pan-cytokeratin antibody (guinea pig polyclonal, Acris, San Diego, CA, USA) and an Alexa488-conjugated anti-guinea pig secondary antibody (Invitrogen, Burlington, ON, Canada) were included in all fluorescence IHC assays. All slides were mounted in DAPI-containing medium (Invitrogen).

Slides were scanned using a HistoRx PM-2000 (Genoptix, Carlsbad, CA, USA) and analysed by AQUAnalysis software (version 2.2.1.7; Genoptix). The tumour compartment was defined as the PCK-positive area for each TMA core, the tumour nuclear compartment was defined as the DAPI-positive area within the tumour compartment, the Ki67 compartment area was defined as the Ki67-positive area within the tumour nuclear compartment ([@bib25]), and the stromal compartment was defined as the vimentin-positive and PCK-negative area ([@bib3]). AQUAnalysis software was used to calculate sCAIX and tumour BAX AQUA scores representing the exposure time-adjusted and lamp-intensity normalised average pixel intensity of each biomarker within the compartment of interest. The algorithm AQUA score determination and background discrimination has been reported previously ([@bib14]). Ki67 expression was reported as the percentage of tumour nuclear area that was positive for Ki67 ([@bib25]).

Statistical analysis
--------------------

Patients were dichotomised by the basal Ki67 expression (percentage of tumour nuclear area positive for Ki67) to define low and high proliferation groups. Pathologists often select the least favourable region of a tumour (e.g., differentiation status) to define the whole tumour. We used this principle to apply our understanding of the biology of our candidate markers and select biologically relevant definitions. Basal Ki67 expression for each OSCC patient was defined as the lowest level measured among triplicate TMA cores; this definition of Ki67 status was most strongly associated with 5-year disease-specific survival (DSS) in a previous evaluation of Ki67 scoring strategies ([@bib25]). CAIX expression in the tissue core, expressing the maximum level of sCAIX among triplicate TMA cores, was used to identify patients with top-quartile CAIX expression in the stromal compartment (sCAIX^hi^) ([@bib5]). We have previously reported that the maximum sCAIX expression associates with significantly worse 5-year DSS in patients with the highest sCAIX.

BAX expression for each patient was defined by the mean BAX expression from triplicate TMA cores. Mean BAX expression was compared in box and whisker plots and Welch\'s *t*-test analyses. The Fisher\'s exact test was used to compare clinical characteristics between patient groups defined by combined sCAIX and Ki67 expression. Kaplan--Meier curves and the logrank test were used to assess the association with 5-year DSS. Survival was measured from the date of diagnosis to the date of death or the date of last follow-up. The impact of clinically significant covariates, including pathologic T stage (pT-stage) and node status (N-stage), was assessed using Cox proportional hazards analyses. All statistical analyses were performed using Stata 12 (StataCorp LP, College Station, TX, USA).

Results
=======

Cohort characteristics
----------------------

Our study adheres to the REMARK criteria ([@bib31]). The median age of patients included in the study was 61.5 years (range: 26--83 years). Median follow-up for the cohort was 50 months and the 5-year survival estimate was 69.6%. Univariate analyses of clinico-pathological characteristics are presented in [Table 1](#tbl1){ref-type="table"}. Frozen section margins were evaluated and were clear in 58 of the 60 resections. ECS status was only reported in 11 of 28 (39%) node-positive patients. Both pT- and N-stage were significantly associated with DSS (logrank *P*\<0.005). All patients were treated with primary surgery and 45 (72%) received post-operative radiotherapy. Two patients received concurrent chemoradiation therapy as treatment for their primary disease but these patients were not analysed or reported separately.

Biomarker expression analysis
-----------------------------

Representative fluorescence IHC images for each biomarker are presented in [Figure 1](#fig1){ref-type="fig"}. CAIX expression was predominantly membranous or cytoplasmic in both the tumour and stromal compartments ([Figure 1A](#fig1){ref-type="fig"}). The median intensity of sCAIX expression in OSCC tumour samples was 1379 (95% CI 442--2315). As expected, tumour Ki67 expression was predominantly nuclear ([Figure 1B](#fig1){ref-type="fig"}). Proliferative (Ki67-positive) cells were observed both in the tumour and stromal compartments. The median basal Ki67 percent positive tumour nuclear area score in OSCC samples was 31.2% (95% CI 17.2--65.6%). Tumour BAX expression was predominantly cytoplasmic ([Figure 1C](#fig1){ref-type="fig"}). The median intensity of BAX expression in OSCC was 4609 (95% CI 2972--6616).

A prognostic signature combining CAIX and Ki67 expression
---------------------------------------------------------

As previously reported, high stromal CAIX expression (sCAIX^hi^) was associated with poor DSS ([@bib4], [@bib5]), ([Figure 2A](#fig2){ref-type="fig"}). Stratification of sCAIX^hi^-expressing tumours by their median basal Ki67 expression identified a group with significantly worse survival; the median survival for sCAIX^hi^ and Ki67^lo^sCAIX^hi^ groups was ∼38 and ∼18 months, respectively ([Figure 2A and B](#fig2){ref-type="fig"}). Patients identified by this signature (top-quartile CAIX expression with below-median basal Ki67 expression; Ki67^lo^sCAIX^hi^) exhibited significantly worse DSS compared with all other patients in the OSCC cohort ([Figure 2C](#fig2){ref-type="fig"}). Patients in the Ki67^lo^sCAIX^hi^ group did not differ significantly by age, gender, clinical stage, pT-stage, differentiation status, smoking history, alcohol history or treatment selection ([Table 1](#tbl1){ref-type="table"}). However, the Ki67^lo^sCAIX^hi^ group was significantly associated with positive pN-stage (*P*=0.007; [Table 1](#tbl1){ref-type="table"}). Patients in this group also exhibited a higher propensity for lymph node metastasis (89% of patients are lymph node positive) compared with patients expressing sCAIX^hi^ alone (69% of patients are lymph node positive).

The independent prognostic impact of Ki67^lo^sCAIX^hi^ was assessed using Cox proportional hazards models. pT-stage (T1/T2 *vs* T3/T4) and pN-stage (N0 *vs* N1/N2) were included with Ki67^lo^sCAIX^hi^ in the multivariate model based on their acknowledged clinical significance in OSCC and their significant association with DSS in univariate analyses ([Table 1](#tbl1){ref-type="table"}). All three variables, pT-stage (HR 1.026 (1.002--1.049), *P*=0.032), pN-stage (HR 6.794 (1.852--24.924), *P*=0.004) and Ki67^lo^sCAIX^hi^ (HR 4.209 (1.387--12.774), *P*=0.011), were independently associated with DSS ([Table 2](#tbl2){ref-type="table"}).

Relevance of prognostic signature to hypoxia
--------------------------------------------

Given that BAX expression is suppressed in hypoxia ([@bib13]; [@bib32]), we analysed the association between our EMH and proliferation-based prognostic signature, and BAX expression. BAX expression was lower in the Ki67^lo^sCAIX^hi^ group compared with the rest of the cohort ([Figure 3A](#fig3){ref-type="fig"}). The difference in BAX expression was negligible when patients were stratified based on sCAIX expression alone ([Figure 3B](#fig3){ref-type="fig"}).

Discussion
==========

In this study, we address the potential confounding effect of proliferative signalling on the association between CAIX and prognosis. We demonstrate that the prognostic utility of CAIX can be improved by considering the hypoxia-independent contribution of proliferative signalling pathways to CAIX expression. Tumours characterised by low proliferation and high sCAIX expression (Ki67^lo^sCAIX^hi^) were associated with significantly worse DSS in univariate and multivariate analyses. Accounting for the contribution of tumour proliferation in our CAIX-based prognostic assay ([@bib5]), by stratifying patients based on tumour ki67 status (Ki67^lo^sCAIX^hi^), identified patients with the most aggressive disease course. These patients also demonstrated the most significant decrease in BAX expression, the downregulation of which is a common feature of hypoxia, ([@bib13]; [@bib32]).

We have previously shown that sCAIX is more strongly associated with patient survival than tumour CAIX ([@bib4], [@bib5]). CAIX expression in the stroma is not confounded by common OSCC-associated somatic mutations such as *CAIX* gene amplification and deletion of the *von Hippel-Lindau* (*VHL*) gene ([@bib39]). Loss of VHL, a regulator of HIF1*α*, has been shown to promote hypoxia-independent expression of CAIX ([@bib18]; [@bib44]). However, sCAIX expression may be affected by proliferation-associated factors that may misrepresent hypoxic status. Although we observed proliferating cells in the stromal compartment, the impact of proliferative signalling in the tumour cells is likely to be most relevant to disease course. As proliferative pathways are predominantly deregulated in the tumour rather than the stroma, we assigned proliferation status based on Ki67 in the tumour cells. Paracrine/autocine growth factor signalling within the tumour microenvironment may lead to HIF1*α* stabilisation in the stroma and upregulate sCAIX expression independent of hypoxia. Additionally, high tumour cell density can lead to peri-cellular hypoxia due to the acute and local depletion of oxygen and nutrients, which could also cause increased sCAIX expression ([@bib11]; [@bib24]). Therefore, the combination of sCAIX and tumour Ki67 expression could identify tumours that are 'functionally hypoxic\'.

It is well recognised that hypoxic tumours are generally associated with poor prognosis ([@bib42]; [@bib21]) and several groups have investigated the role of both hypoxia and proliferation in OSCC and other head and neck cancers ([@bib28]; [@bib16]; [@bib26]). Although a stromal CAIX and tumour Ki67 signature has not been previously explored, there is some support in the existing literature ([@bib16]) for our combined hypoxia and proliferation-based prognostic signature providing a more biologically relevant definition of hypoxic tumours than sCAIX alone. Our Ki67 and CAIX-based signature identifies a population of OSCC patients with significantly worse prognosis than sCAIX alone. Furthermore, it has been reported that the poor prognosis associated with tumour hypoxia is partly attributed to hypoxia-induced tumour cell migration and invasion ([@bib40]). We report that patients with poorly proliferative tumours expressing high sCAIX (Ki67^lo^sCAIX^hi^), exhibit a higher propensity for lymph node metastasis compared with patients expressing sCAIX^hi^ alone. Despite this strong correlation between lymph node metastasis and Ki67^lo^sCAIX^hi^-defined hypoxia, we demonstrate that Ki67^lo^sCAIX^hi^ is an independent prognostic factor in our OSCC cohort after adjusting for pT- and pN-stage in multivariate analysis. Lastly, hypoxic tumours have been shown to be resistant to apoptosis-inducing stimuli ([@bib43]). BAX expression is downregulated in hypoxia ([@bib13]) and suppression of the pro-apoptotic BAX/BAK pathways is required for tumour cells to survive in hypoxic conditions and evade treatment-induced apoptosis ([@bib32]). Accordingly, we found that BAX expression was markedly lower in Ki67^lo^sCAIX^hi^ tumours compared with tumours defined by sCAIX^hi^ alone.

The observation of discrepancies between different methods for identifying hypoxic tumours has led to the development of mRNA expression-based hypoxia profiles. These profiles are reported to more accurately identify hypoxic tumours by accounting for multiple hypoxia-associated factors ([@bib41]). However, while this is promising for research applications, mRNA profile-based testing has not been broadly adopted in the clinic due to several logistical challenges. Currently, few mRNA profile-based tests are in routine clinical use for treatment selection in cancer; the most prominent of these is the Genomic Health 21-gene Recurrence Score test for predicting recurrence after anti-oestrogen therapy in early-stage breast cancer ([@bib35]). However, this test may soon be replaced by a more clinically feasible four-component IHC-based equivalent, IHC4 ([@bib12]).

The two-component 'functional hypoxia\' signature (Ki67 and sCAIX) proposed in this study demonstrates a significant improvement over the use of sCAIX alone for identifying patients with poor prognosis. A Ki67/sCAIX-based IHC test could be developed and routinely applied in the clinic to detect functionally hypoxic tumours and direct the use of several promising treatment strategies ([@bib43]; [@bib2]). Also, such a test can be applied to tumours that are not treated surgically, to identify patients that will benefit from the addition of hypoxia-targeting/sensitising therapies to existing chemoradiation regimens. Additional biomarkers could potentially be incorporated to further tailor this signature to specific tumour types ([@bib10]) or to specific hypoxia-sensitising/targeting treatments. However, testing the inclusion of additional markers will require a larger patient cohort than the one reported in this study.

Our study is limited by its retrospective design and the lack of corroborative pO~2~ or pimonidazole measurements. ECS is an important prognostic factor in OSCC and its incomplete reporting at the time that these patients were treated is a further limitation of our study. Additionally, the Ki67^lo^sCAIX^hi^ group was relatively small, leading to the possibility of 'over-fitting\' the data. This and the *post-hoc* definition of survival groups can both be addressed by replication in an independent OSCC cohort. However, our results strongly suggest that using combined sCAIX and tumour Ki67 expression, to account for hypoxia-independent CAIX expression, could lead to the development of a cost-effective and clinically feasible test to efficiently identify patients with unfavourable outcomes that may indicate functionally hypoxic tumours.

We thank Dr. T. Wayne Matthews for contributing patients to this study and Dr. E.M. Long for her help with editing of the manuscript and figure preparation. We also gratefully acknowledge the Ohlson Research Initiative for funding this project.

![**Fluorescent immunohistochemical staining using the HistoRx AQUAnalysis platform.** Representative fluorescence immunohistochemistry images for (**A**) sCAIX, (**B**) Ki67, and (**C**) BAX expression in OSCC samples. Upper and lower panels present examples of low and high biomarker expression, respectively. Merged images are pseudo-coloured blue for DAPI, green for pan-cytokeratin, red for the biomarker of interest, and greyscale for vimentin. AQUA scores for BAX and sCAIX and the percent positive tumour nuclear area for Ki67 are indicated in the merged images.](bjc2013533f1){#fig1}

![**Univariate survival analysis of prognostic signatures in OSCC.** Kaplan--Meier curves and logrank *P*-values for disease-specific survival in (**A**) all OSCC patients dichotomised based on sCAIX expression status, (**B**) OSCC patients with high sCAIX dichotomised based on Ki67 expression, and (**C**) all OSCC patients dichotomised based on Ki67^lo^sCAIX^hi^ status.](bjc2013533f2){#fig2}

![**BAX expression analysis in patients stratified by sCAIX and Ki67 expression status.** Box and whisker plots comparing BAX expression in the OSCC cohort by (**A**) sCAIX expression status alone or (**B**) Ki67^lo^sCAIX^hi^ status. Welch\'s *t*-test *P*-values are reported.](bjc2013533f3){#fig3}

###### Demographic and clinico-pathological characteristics of the study cohort

  **Characteristics**          **No. of cases (%)**   **Ki67**^**lo**^**sCAIX**^**hi**^ (***n*****=9)**   **Ki67**^**hi**^ **or Ki67**^**lo**^**sCAIX**^**lo**^ (***n*****=51)**   **Fisher\'s exact (*****P*****-value)**   **Logrank (*****P*****-value)**
  ---------------------------- ---------------------- --------------------------------------------------- ------------------------------------------------------------------------ ----------------------------------------- ---------------------------------
  **Age, years**                                                                                                                                                                                                             
  \<60                         28 (47)                4                                                   24                                                                       0.588                                     0.534
  ⩾60                          32 (53)                5                                                   27                                                                                                                  
  **Gender**                                                                                                                                                                                                                 
  Male                         42 (70)                5                                                   37                                                                       0.257                                     0.875
  Female                       18 (30)                4                                                   14                                                                                                                  
  **Pathologic T stage**                                                                                                                                                                                                     
  T1+T2                        32 (53)                4                                                   28                                                                       0.389                                     0.004\*
  T3+T4                        27 (45)                5                                                   22                                                                                                                  
  Unknown                      1 (2)                  0                                                   1                                                                                                                   
  **Pathologic N stage**                                                                                                                                                                                                     
  N0                           32 (53)                1                                                   31                                                                       0.007\*                                   \<0.001\*
  N1+N2                        28 (47)                8                                                   20                                                                                                                  
  **Differentiation status**                                                                                                                                                                                                 
  Well                         10 (17)                0                                                   10                                                                       0.198                                     0.077
  Moderate                     35 (58)                6                                                   29                                                                                                                  
  Poor                         7 (12)                 2                                                   5                                                                                                                   
  Unknown                      8 (13)                 1                                                   7                                                                                                                   
  **Smoking history**                                                                                                                                                                                                        
  Never                        13 (22)                3                                                   10                                                                       0.299                                     0.708
  Ever                         47 (78)                6                                                   41                                                                                                                  
  **Alcohol history**                                                                                                                                                                                                        
  Never+occasional             28 (47)                4                                                   24                                                                       0.604                                     0.086
  Moderate+heavy               26 (43)                4                                                   22                                                                                                                  
  Unknown                      6 (10)                 1                                                   5                                                                                                                   
  **Treatment**                                                                                                                                                                                                              
  Surgery                      15 (25)                2                                                   13                                                                       0.601                                     0.125
  Surgery+radiation            45 (72)                7                                                   38                                                                                                                  

###### Cox proportional hazards analysis of disease-specific survival

                                                  **Univariate**         **Multivariate**                               
  ----------------------------------------- --------------------------- ------------------- --------------------------- -------------------
  **Covariates**                             **Hazard ratio (95% CI)**   ***P*****-value**   **Hazard ratio (95% CI)**   ***P*****-value**
  Ki67^lo^sCAIX^hi^ (no *vs* yes)              7.175 (2.522--20.414)          \<0.001          4.209 (1.387--12.774)           0.011
  Pathological T stage (T1/T2 *vs* T3/T4)      1.010 (0.990--1.031)            0.315           1.026 (1.002--1.049)            0.032
  Pathological N stage (N0 *vs* N1/N2)         6.882 (2.268--20.885)           0.001           6.794 (1.852--24.924)           0.004

Abbreviation: CI=confidence interval.
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